Treatments for specific subsets of patients with adenocarcinoma of unknown primary

Histologic type	Clinical feature	Treatment recommendation
Adenocarcinoma	Females with isolated axillary adenopathy	Treat as stage II breast cancer
	Females with peritoneal carcinomatosis	Treat as stage III ovarian cancer
	Males with elevated PSA or blastic bone metastases	Treat as advanced prostate cancer
	Colon cancer profile	Treat as advanced colon cancer
	NSCLC profile	Treat as advanced NSCLC
	RCC profile	Treat as advanced RCC
	Thyroid carcinoma profile	Treat as advanced follicular/papillary thyroid carcinoma
Adenocarcinoma or PDC	Single metastatic lesion	Definitive local therapy (resection and/or radiation therapy)

Approximately 30 to 35% of patients with adenocarcinoma of unknown primary fit into one of these subsets with specific treatment implications.

PSA: prostate-specific antigen; NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma; PDC: poorly-differentiated carcinoma.

Graphic 134744 Version 1.0